OncoZenge AB (publ) (OM: ONCOZ)
Health Care · Pharmaceuticals · SE
Skr5.68
-6.12% today · -7.4% 1Y
OncoZenge AB (publ) (OM: ONCOZ) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $8.94M and employs 1 people.
Over the last twelve months the share price has lost 7.4%, trading between 4.52 and 10.28.
Tweenvest scores OncoZenge AB (publ) across four factors: quality 27/100, value 40/100. Its strongest factor is value.
ONCOZ price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $8.94M
- Revenue (TTM)
- $7.46K
- P/E
- —
- EPS
- -1.85
- Dividend yield
- —
- Beta (5Y)
- 1.33
- 52-week high
- Skr10.28
- 52-week low
- Skr4.52
- Avg volume (3M)
- —
- Shares outstanding
- 14.05M
- Employees
- 1
- Next earnings
- —
About OncoZenge AB (publ)
OncoZenge AB (publ) operates as a pharmaceutical company with a focus on developing medical solutions that offer supportive care for cancer patients. A significant product in its pipeline is BupiZenge, which has successfully completed Phase 2 clinical trials for the management of oral mucositis. This company was established in 2020 and conducts its operations from its headquarters in Bromma, Sweden. Notably, OncoZenge AB (publ) is a subsidiary entity of Moberg Pharma AB (publ).
- ISIN
- SE0015504097
- Founded
- 2020
- Listed since
- Feb 12, 2021
- Exchange
- OMX Nordic Exchange Stockholm
- Currency
- SEK
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,233.66 | -1.06% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $273.14 | +0.04% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $156.45 | +3.84% |
| Roche Holding AGSWX: ROP | $371.62B | CHF373.80 | +0.92% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £124.76 | +3.02% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.57 | +2.15% |
Figures last refreshed Aug 18, 2026.